Papilloma Virus Vaccine Therapy in Treating Young Patients With Recurrent Papilloma of the Larynx

University of Medicine and Dentistry of New Jersey

Overview

RATIONALE: Vaccines made from papilloma virus cells may make the body build an immune response to and kill papilloma cells. PURPOSE: Phase II trial to study the effectiveness of papilloma virus vaccine in treating young patients with recurrent papilloma of the larynx.

OBJECTIVES: I. Determine the immune response in patients with juvenile papilloma of the larynx treated with autogenous vaccine derived from each patient's own tumor. OUTLINE: Patients receive autogenous papilloma vaccine intradermally and subcutaneously weekly for 20 weeks. PROJECTED ACCRUAL: Not specified

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Conditions

Precancerous Condition

Interventions

autologous tumor cell vaccineBIOLOGICAL

Eligibility

Sex: ALLMin age: 1 Year

Medical Language ↔ Plain English

DISEASE CHARACTERISTICS: Diagnosis of severe recurrent juvenile papilloma of the larynx requiring surgery at least 4 times per year Condition must have existed for more than 1 year PATIENT CHARACTERISTICS: Age: 1 and over Performance status: Not specified Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified PRIOR CONCURRENT THERAPY: See Disease Characteristics

Locations (1)

New Jersey Medical School

Newark, New Jersey, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.